The Trump administration has proposed rules banning federal funding for gender-affirming care and removing gender dysphoria’s disability status, while the FDA has issued warning letters to breast binder manufacturers, intensifying restrictions on transgender healthcare access.
In a sweeping move on December 18, 2025, the Trump administration unveiled a series of proposed rules that would effectively ban Medicaid and CHIP from covering gender-affirming care, while also barring hospitals that provide such services from participating in Medicare or Medicaid funding. Health Secretary Robert F. Kennedy Jr. declared that sex-rejecting procedures are neither safe nor effective for children with gender dysphoria, reinforcing the administration's stance against gender-affirming treatments for minors.
Key highlights from the announcement include
-
Major policy shift : Hospitals performing gender-affirming care for minors will no longer be eligible for federal Medicare or Medicaid funding, drastically limiting access for vulnerable populations
-
Medical justification: Secretary Kennedy cited a new HHS declaration stating that sex-rejecting procedures do not meet the standards of safe and effective treatment for children experiencing gender dysphoria
-
Disability status revoked: The administration is moving to remove gender dysphoria’s classification as a disability, further eroding protections and support for transgender individuals
-
FDA crackdown: The FDA has issued warning letters to 12 manufacturers of breast binders, signaling broader regulatory scrutiny of products associated with gender-affirming care
These changes are part of a broader campaign to roll back access to gender-affirming care, which critics argue will harm the mental and physical health of transgender people, especially youth. Medical organizations, including the American Medical Association and American Academy of Pediatrics, have consistently affirmed the necessity and effectiveness of such care, citing peer-reviewed research that shows improved outcomes for those who receive it
Source: U.S. Department of Health and Human Services, FDA, Washington Post, NPR